Program

 

All sessions will be held at the Hyatt Regency Jersey City (Manhattan Ballroom, 9th Floor).

The preliminary program for the 21st International Conference on Alzheimer’s Drug Discovery will be posted mid-winter.  Until then, we invite you to review our 20th edition’s program:

Sunday, September 15, 2019

5:00–7:00pm Registration

Monday, September 16, 2019

8:00am–5:30pmRegistration
8:00–9:00amContinental Breakfast
9:00–9:20Welcome & Introductory Notes
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
9:20–9:50KEYNOTE: Extracellular Vesicle Biomarkers Revolutionize Preclinical Diagnosis of AD and Assessment of Treatment Responses in Clinical Trials
Dimitrios Kapogiannis, MD—National Institutes of Health
9:50-10:00Q&A
Session I: SMALL MOLECULE APPROACHES FOR ALZHEIMER’S DISEASE
Chair: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
10:00–10:05Session Overview: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
10:05–10:25Q134R: Novel Small Chemical Compound with NFAT Inhibitory Properties Ameliorates Synaptic Deficits in a Mouse Model of Alzheimer's Disease
Christopher Norris, PhD—University of Kentucky
10:25–10:35Q&A
10:35–10:55 Inhibiting Ryanodine Receptors, an ER Calcium Channel, to Prevent Synaptic Pathology and Protein Mishandling
Grace (Beth) Stutzmann, PhD—Chicago Medical School/NeuroLucent, Inc
10:55–11:05Q&A
11:05–11:35EXHIBITOR SESSION BREAK
11:35–11:55Design and Exploration of NLRP3 Inhibitors for Neurodegenerative Disorders
Shijun Zhang, PhD—Virginia Commonwealth University
11:55am–12:05pmQ&A
12:05–12:25Pharmacological Inhibition of EP2 Receptors Suppress Neuroinflammation in the Female 5xFAD Mice, but not in the Male 5xFAD Mice
Thota Ganesh, PhD—Emory University
12:25–12:35Q&A
12:35–1:05POSTER SESSION
1:05–2:00
LUNCH
Session II: NOVEL APPROACHES FOR FRONTOTEMPORAL DEMENTIA
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
2:00–2:05Session Overview: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
2:05–2:25TDP-43 Proteinopathies: Challenges and Opportunities for a Pathology-specific Biofluid Test
Mari DeMarco, PhD—University of British Columbia
2:25–2:35Q&A
2:35–2:55Human Microglial and Neuronal Models of Frontotemporal Dementia and Strategies to Rescue Progranulin Haploinsufficiency
Steven Finkbeiner, MD, PhD—Gladstone Institutes/University of California, San Francisco
2:55–3:05Q&A
3:05–3:25Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: the Neurofilament Light Surveillance Project (NSP)
Rodney Pearlman, PhD—The Bluefield Project to Cure FTD
3:25–3:35Q&A
3:35–3:55Non-invasive Brain Stimulation to Restore Cortical Connectivity in FTD
Alberto Benussi, MD—University of Brescia
3:55–4:05Q&A
4:05–4:35EXHIBITOR SESSION BREAK
4:35–5:20 EMERGING CONCEPTS: DATA BLITZ
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation

Neuron-targeted Caveolin-1 Preserves Hippocampal Neuroplasticity and Memory in AD Mice
Young Investigator #1: Shanshan Wang, MD, PhD—University of California, San Diego

Treatment with AUY954, a Selective Sphingosine-1-phosphate Receptor 1 Agonist, Reduces Early Development of AI Pathology and Neuroinflammation in a Mouse Model of Alzheimer's Disease
Young Investigator #2: Christina Tognoni, PhD—Boston University/VA Boston Healthcare System

Memory Impairments and Synaptic Failure in Tg19959 AD Model Mice Are Alleviated by Eef2k Inhibitor A-484954
Young Investigator #3: Nicole Kasica, PhD (cand.)—Wake Forest University
5:20–5:30Closing Remarks and Announcement of Young Investigator Scholarships
Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
5:30–7:00NETWORKING RECEPTION

Tuesday, September 17, 2019

7:30–8:20amContinental Breakfast
8:20–8:50SPECIAL SESSION: NIA's Alzheimer’s and Related Dementias Translational Research Funding Opportunities
Zane Martin, PhD—National Institute on Aging
8:50–9:20 KEYNOTE: The Use of Platform Trials in CNS Disorders
Sabrina Paganoni, MD, PhD—Massachusetts General Hospital/Harvard University
9:20-9:30Q&A
Session III: CLINICAL TRIALS IN ALZHEIMER’S DISEASE
Chair: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
9:30–9:35 Session Overview: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
9:35–9:55Rasagiline Rescue (R2): A Double-Blind Placebo Controlled Trial for Mild to Moderate Alzheimer’s Disease
Jeffrey Cummings, MD, ScD—Cleveland Clinic
9:55–10:05Q&A
10:05–10:25Clinical Biomarker Evidence for Target Engagement, Reduction of Synaptic Damage and Disease Modification in Alzheimer’s Patients Treated with CT1812 (ElaytaTM)
Susan Catalano, PhD—Cognition Therapeutics
10:25–10:35Q&A
10:35–11:05EXHIBITOR SESSION BREAK
11:05–11:25Vafidemstat: The First Epigenetic Approach in Alzheimer's Disease
Roger Bullock, MBBS—Oryzon
11:25–11:35Q&A
11:35–11:55Vascular Approaches for Alzheimer’s Treatment
Ihab Hajjar, MD—Emory Health Care
11:55am–12:05pmQ&A
12:05–12:35POSTER SESSION
12:35–1:15LUNCH
Session IV: NOVEL BIOMARKER APPROACHES
Chair: Nicole Bjorklund, PhD—Alzheimer’s Drug Discovery Foundation
1:15–1:20Session Overview: Nicole Bjorklund, PhD—Alzheimer’s Drug Discovery Foundation
1:20 –1:40FDG PET, Tau PET, and MR Imaging Biomarkers in Alzheimer’s Disease Therapeutic Trials
Dawn Matthews, MS, MBA—ADMdx
1:40–1:50Q&A
1:50–2:10Resilience Biomarker NPTX2 and AD Progression
Paul Worley, MD—Johns Hopkins University
2:10–2:20Q&A
2:20–2:40The Utility of cFLIP and MCL I and their Regulatory MicroRNAs as Novel Biomarkers of Alzheimer's Disease
Esmerina Tili, PhD—OSU/Gnome Diagnostics, LLC
2:40–2:50Q&A
2:50-3:10Ocular Approaches for Alzheimer’s Diagnosis
Swati More, PhD—University of Minnesota
3:10-3:20Q&A
3:20-3:30pmClosing Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation